Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Noronha A, Belugali Nataraj N, Lee JS, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, Sinha S, Brandis A, Kerr DL, Wu W, Sekar A, Giri S, Chung Y, Drago-Garcia D, Danysh BP, Lauriola M, Fiorentino M, Ardizzoni A, Oren M, Blakely CM, Ezike J, Wiemann S, Parida L, Bivona TG, Aqeilan RI, Brugge JS, Regev A, Getz G, Ruppin E, Yarden Y. Noronha A, et al. Among authors: yarden y. Cancer Discov. 2022 Nov 2;12(11):2666-2683. doi: 10.1158/2159-8290.CD-22-0111. Cancer Discov. 2022. PMID: 35895872 Free PMC article.
Consistency test of the cell cycle: roles for p53 and EGR1.
Zwang Y, Oren M, Yarden Y. Zwang Y, et al. Among authors: yarden y. Cancer Res. 2012 Mar 1;72(5):1051-4. doi: 10.1158/0008-5472.CAN-11-3382. Epub 2012 Feb 7. Cancer Res. 2012. PMID: 22315347 Free PMC article. Review.
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.
Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, Yarden Y. Ferraro DA, et al. Among authors: yarden y. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1815-20. doi: 10.1073/pnas.1220763110. Epub 2013 Jan 14. Proc Natl Acad Sci U S A. 2013. PMID: 23319610 Free PMC article.
Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.
Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Sharon-Sevilla M, Lindzen M, Sharma K, Nevo N, Feldman M, Carvalho S, Cohen-Dvashi H, Kedmi M, Ben-Chetrit N, Chen A, Solmi R, Wiemann S, Schmitt F, Domany E, Yarden Y. Lauriola M, et al. Among authors: yarden y. Nat Commun. 2014 Oct 3;5:5073. doi: 10.1038/ncomms6073. Nat Commun. 2014. PMID: 25278152 Free PMC article.
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.
Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, Lindzen M, Kedmi M, Lauriola M, Shulman Z, Barr H, Seger D, Ferraro DA, Pareja F, Gil-Henn H, Lapidot T, Alon R, Milanezi F, Symons M, Ben-Hamo R, Efroni S, Schmitt F, Wiemann S, Caldas C, Ehrlich M, Yarden Y. Ben-Chetrit N, et al. Among authors: yarden y. Sci Signal. 2015 Jan 20;8(360):ra7. doi: 10.1126/scisignal.2005537. Sci Signal. 2015. PMID: 25605973
Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression.
Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, Mancini M, Nataraj N, Kedmi M, Roth L, Köstler W, Zeisel A, Yitzhaky A, Zylberg J, Tarcic G, Eilam R, Wigelman Y, Will R, Lavi S, Porat Z, Wiemann S, Ricardo S, Schmitt F, Caldas C, Yarden Y. Cohen-Dvashi H, et al. Among authors: yarden y. EMBO Mol Med. 2015 Mar;7(3):299-314. doi: 10.15252/emmm.201404134. EMBO Mol Med. 2015. PMID: 25678558 Free PMC article.
351 results